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Introduction
Potentially reversible, immune-mediated, sensorineural hearing 
loss (SNHL) can be divided into 2 subgroups: autoimmune inner 
ear disease (AIED) and sudden SNHL (SSNHL). Patients with AIED 
usually experience multiple episodes of rapid hearing loss, either 
concurrently or sequentially, in both ears, whereas SSNHL is usually 
a unilateral, isolated event. The mechanisms that control cortico-
steroid-responsive immune-mediated SNHL remain enigmatic, in 
large part, because AIED is a rare disease, worthy of orphan disease 
classification, and SSNHL is likely heterogeneous in etiology. For 
patients that experience an acute, sensorineural decline in hearing, 
timely corticosteroid administration may result in preservation of 
some or all hearing in approximately 60% of patients with either 
AIED (1) or SSNHL (2). Unfortunately, alternate medical therapies 
for the 40% that fail to respond to corticosteroids have proven large-
ly ineffectual. Therefore, the majority of interventions following cor-
ticosteroid failure are rehabilitative, involving either hearing aids or 
cochlear implants. Interestingly, the influence of plasma cytokines 
has not been investigated to any great degree in this disorder, largely 
because the events in the cochlea may not be reflected in the periph-
eral blood immune cells (PBMCs). Furthermore, since AIED is a rare 
disease, studies of these patients are often difficult to implement.
We initially examined patients with end-stage AIED, who were 
candidates for cochlear implants, and compared them with cochle-
ar implant candidates with nonimmunologic etiologies of hear-
ing loss. We harvested cochlear perilymph at the time of cochlear 
implant surgery and used it to stimulate autologous PBMCs. We 
identified that the 2 groups differed with respect to expression of 
the IL-1 type II decoy receptor (IL-1R2) in PBMCs in response to 
autologous perilymph (3). The decoy receptor sequesters IL-1, yet 
has no downstream signaling, thereby preventing inflammation 
(4). These initial observations led to further investigation of the 
cytokines in the peripheral blood of steroid-sensitive and steroid-
resistant AIED patients. Consistent with the increased expression 
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of which enrolled into this single-center, phase I/II open-label 
study (Figure 1). Of these 13 patients, 12 received anakinra, as 
patient LIJ-10 passed the screening process, but was not started on 
drug because of development of a systemic infection in the inter-
im. Demographics of age, gender, concurrent autoimmune con-
ditions, other diseases, and medications are outlined in Table 1. 
Of the 12 patients, 10 were evaluable for efficacy (Figure 1), as 2 
patients were unable to complete the requisite initial 28 days of 
therapy required to assess efficacy. Results reported follow the 
2010 CONSORT guidelines as applicable (13). Notably, both the 
patient reporting uveitis (LIJ-03) and the single teenaged patient 
(LIJ-09) were identified to be sequence-negative for NLRP3 muta-
tions, excluding a diagnosis of MWS.
Efficacy. As per protocol, 10 patients were enrolled in the first 
stage, and 8 of these completed the 84-day therapy period at the 
time of interim analysis. Of these 8, 5 were classified as responders 
by PTA score, which triggered enrollment into the second stage. 
At the time enrollment began in the second stage, patients LIJ-09 
and LIJ-10 had not yet completed the 84-day observation period 
(but ultimately yielded 1 responder and 1 that never instituted 
treatment). During this time, 3 stage II patients were enrolled, for 
a trial total of 13.
Of the total 13 subjects, 2 withdrew from treatment within the 
first 28 days, and 1 never initiated treatment, leaving 10 subjects 
evaluable for efficacy assessment. Per protocol, responsive patients 
were defined as having ≥5 decibel (dB) improvement in PTA in the 
of the IL-1R2 decoy receptor in steroid-resistant AIED patients 
(3), we observed increased expression of IL-1β in these steroid-
resistant individuals (5). Moreover, whereas dexamethasone was 
unable to prevent IL-1β release in the PBMCs of these patients, 
anakinra effectively prevented IL-1β release (5). Anakinra is an IL-1 
receptor antagonist that competitively inhibits IL-1 binding to the 
cognate IL-1 type I receptor, thereby blocking the biologic activity 
of IL-1β and IL-1α (6). This observation became the rationale for 
the present clinical trial in steroid-resistant AIED patients.
SNHL related to IL-1β expression has also been observed in 
a rare disease, Muckle-Wells disease (MWS), in which a gain-of-
function mutation in NLRP3 results in excessive IL-1β release (7, 8). 
In this autosomal-dominant disease, patients experience skin 
rashes, periodic fevers, and SNHL. Unlike MWS patients, AIED 
patients do not have an afflicted first-degree relative, skin rash, 
or fever. Moreover, although the majority of AIED patients are 
initially steroid responsive (70%), that response is lost over time 
in all but 14% of patients (9). Furthermore, whereas IL-1β inhibi-
tion is quite effective at controlling the systemic manifestations 
of MWS, only 3 of 14 patients experienced minor improvement 
in auditory acuity with IL-1 inhibition (10), despite isolated case 
reports of significant greater hearing recovery (11, 12).
Results
Characteristics of the study population. During a 3-year period 
(December 2010 to January 2014), 14 patients were screened, 13 
Figure 1. CONSORT flow diagram. For enrollment, all patients must have been treated with a 28-day course of prednisone and have experienced no clinical 
improvement, as assessed by PTA and WRS. All patients that met enrollment criteria were allocated to receive the intervention (n = 13). Of the 13 subjects, 
1 never received anakinra. Of the 12 patients that received anakinra, 2 were unable to complete the initial 28 days of therapy, leaving 10 subjects evaluable 
for the efficacy assessment.
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improvement was limited, and may have been artificially low due 
to a ceiling effect: the patient’s starting WRS score was 88%, which 
improved to 90% at the end of 28 days and to 100% by the 84th 
day. By the best interval response (see Figure 3), this patient would 
be classified as a nonresponder. Because by both endpoints, PTA 
and WRS, the criterion of ≥6 responders of a maximum 29 to reject 
the null hypothesis was achieved, the trial was prematurely termi-
nated at the recommendation of the Data and Safety Monitoring 
Board (DSMB), since evidence for efficacy had been supported. 
Of the patients treated with anakinra in this clinical trial, there did 
not appear to be a correlation between audiometric configuration 
and the ability to respond: patients derived benefit with up-sloping, 
down-sloping, flat, and U-shaped audiograms (data not shown).
Although this was not a randomized clinical trial, the results 
could also be interpreted by an intention-to-treat (ITT) analysis. 
There were a total of 13 subjects enrolled, 1 of whom could not start 
the trial, due to logistical reasons unrelated to the trial itself. We 
would not include this subject in the ITT analysis. Of the remain-
ing 12 patients, 2 dropped out due to toxicity (intolerable injection 
site reactions) and would be counted in the ITT analysis, yielding 
a response rate of 7 of 12 (58%). Even this more conservative ITT 
rate of 58% is substantially higher than our initial hypothesis of a 
30% response rate being clinically meaningful.
Adverse events and subject withdrawals. Injection site reactions 
were the most common adverse event, observed in approximately 
70% of patients. This observed rate was consistent with use of 
anakinra in other diseases (15). Of the 13 eligible patients, 2 were 
withdrawn from further study during the anakinra treatment phase: 
active ear, or as having ≥12% improvement in WRS, in response to 
anakinra at any point during the 28th to 84th day. Among the 10 
evaluable subjects (those who completed 84 days of therapy), 7 of 10 
(patients LIJ-01, LIJ-02, LIJ-04, LIJ-05, LIJ-07, LIJ-09, and LIJ-11; 
70%) met the criteria for response by PTA, and 7 of 10 (patients 
LIJ-01, LIJ-02, LIJ-04, LIJ-06, LIJ-07, LIJ-09, and LIJ-11; 70%) met 
the criteria of response by WRS. The results comparing anakinra 
responders and nonresponders were statistically significant for 
PTA and WRS (both P = 0.02, Mann-Whitney test; Figure 2). In 
a prior clinical trial that evaluated the efficacy of methotrexate in 
steroid-sensitive AIED, therapeutic efficacy as measured by pure 
tones was defined as either a 15 dB improvement at 1 frequency or 
a 10 dB improvement at 2 contiguous frequencies (14). This effi-
cacy assessment was difficult to use in the present study because 
of its long duration (264 days) and multiple points of assessment, 
and would not account for possible simultaneous or sequential 
improvements and declines at different frequencies. Nonetheless, 
we did assess whether the enrolled subjects met the criteria for 
PTA improvement based on the existing criteria. Specifically, we 
queried whether the criteria for improvement were met during the 
treatment period, relative to the initial audiogram prior to starting 
anakinra. Notably, when using the criteria set forth in the metho-
trexate trial, the results yielded 1 additional responder: patient 
LIJ-06 now met the definition for responder by PTA as well. As a 
result, in a per-protocol assessment, an 80% response rate would 
be achieved using these alternate criteria for clinical improve-
ment in PTA. WRS criteria for improvement were the same for 
this trial and prior trials. Interestingly, for patient LIJ-05, WRS 
Table 1. Demographics of enrolled subjects
Patient Demographics Autoimmune disease/ 
significant medical history
Concomitant medications  
at enrollment
Anakinra study  
treatment
Additional anakinra 
treatment given after 
84-day course
LIJ-01 37-year-old female None Calcium-D, multivitamin Completed 84 days Yes
LIJ-02 49-year-old female Grave’s disease (age 30 years; treated  
with radioactive iodine)
Synthroid, Dyazide,  
vitamin D, multivitamin
Completed 84 days No
LIJ-03 33-year-old female Meningitis, asthma, kidney stones Dyazide, multivitamins,  
birth control pill, Allegra
Treatment aborted prior to  
28-day course
N/A
LIJ-04 46-year-old female Hypertension, elevated cholesterol Singulair, simvastin, Zyrtec, Ambien, K-LOR, 
Dyazide, Zoloft, Flonase, allergy shots
Completed 84 days No
LIJ-05 61-year-old male Psoriasis Potassium Completed 84 daysA NoA
LIJ-06 54-year-old male Prior myocardial infarction/stent 
insertion, hypertension
Metaprolol, Vytorin, lisinopril,  
Nexium, aspirin, Lovanza, vitamin D,  
Niaspan, calcium, Uroxatrol
Completed 84 days Yes
LIJ-07 53-year-old male Asthma Zocor, Combivent, Elavil, Valium Completed 84 days No
LIJ-08 46-year-old male None Dyazide, aspirin, vitamins Completed 84 days No
LIJ-09 15-year-old female None None Completed 84 days Yes
LIJ-10 64-year-old male Hyperthyroidism None No study treatment initiated N/A
LIJ-11 59-year-old male Ulcerative colitis, melanoma  
(20 years prior), septal squamous cell 
carcinoma (9 years prior)
Diamox, Asacol, Librax, Xanax Completed 84 days Yes
LIJ-12 41-year-old male None None Completed 84 days No
LIJ-14 57-year-old female None Multivitamin Treatment aborted prior to  
completion of first 28-day course
N/A
APatient refused to stop study medication.
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LIJ-06, and LIJ-09). The relapse was associated with increasing 
IL-1β, although a common absolute threshold value was not identi-
fied for relapse. Notably, although patient LIJ-08 was considered an 
anakinra failure, upon discontinuing drug, her IL-1β levels declined 
and her hearing clinically improved (Figure 3). These findings sug-
gest that although anakinra was not effective in modulating IL-1β 
levels in this patient, reduction in her circulating IL-1β appeared to 
be linked to audiometric improvement. Plasma levels of IL-1α were 
also measured at all time points in each subject. No IL-1α could be 
detected in the samples assayed (data not shown).
Discussion
Here, anakinra demonstrated clinical efficacy in this small sample 
of corticosteroid-resistant AIED patients. Prior to these studies, 
no effective therapies have been identified for corticosteroid-
resistant AIED patients. Moreover, no alternative effective thera-
pies have been identified in corticosteroid-sensitive patients (14, 
16, 17). Finally, even gains in steroid-sensitive AIED patients using 
corticosteroid therapy may be limited. In the serial audiometry 
trial for AIED, the average hearing improvement in AIED patients 
after 1 month of corticosteroid therapy was 4.1 dB for PTA and 7% 
for WRS (1). During the anakinra trial, the average PTA improve-
ment was 12 dB in anakinra responders compared with 3 dB in 
nonresponders (Figure 2A). Similarly, the WRS improvement was 
28% in anakinra responders and 6% in nonresponders (Figure 2B). 
Especially in instances of more significant hearing loss, WRS 
improvements were more clinically significant, as WRS scores 
reflect speech comprehension and therefore can distinguish 
the ability (or lack thereof) to derive benefit from hearing aids. 
Although the anakinra study had substantially fewer enrollees, 
the response rate is certainly encouraging compared with the gold 
standard of corticosteroid responses.
In patients with MWS, only minor improvements in auditory 
acuity have been observed (10), which suggests that corticoste-
roid-resistant AIED is a distinct disease process. This distinction 
is further supported by the fact that unlike MWS, in which inheri-
tance is autosomal-dominant, in AIED we are yet to identify an 
afflicted first-degree relative. Furthermore, whereas in MWS, the 
audiometric pattern observed is usually a high-frequency SNHL, 
in the AIED patient cohort, the audiometric pattern was highly 
variable (data not shown) and did not correlate with the ability to 
respond to anakinra.
One of the most difficult aspects in conducting studies on AIED 
patients is the fluctuating nature of the hearing loss, and the poten-
tial for interpretation of efficacy of an intervention rather than 
improvement as a natural fluctuation of disease. In these studies, 
reduction of plasma IL-1β correlated with clinical hearing improve-
ment within the first 28 days of anakinra therapy in patients LIJ-02, 
LIJ-04, LIJ-07, LIJ-09, and LIJ-11. Although hearing fluctuation 
was observed during both the 84-day drug intervention period 
patients LIJ-03 and LIJ-14 did not complete the initial 28 days 
of treatment because of intolerable injection site reactions. Dur-
ing the observational period, 3 patients were withdrawn. Patient 
LIJ-05, one of the responders, was terminated from further trial 
participation at day 84, as the patient refused to discontinue drug. 
Patient LIJ-12 withdrew at visit 5 because of failure of drug efficacy. 
In patient LIJ-07, use of anakinra appeared to modulate the ability 
to respond to steroids: the patient initially responded to anakinra, 
but subsequently worsened by day 84. He was placed on predni-
sone at day 84, and rapidly became corticosteroid responsive at 
that point, whereas he previously failed to respond to prednisone. 
He withdrew from the study following the steroid therapy.
Laboratory studies demonstrated few abnormalities and 
no evidence of neutropenia. No elevations of creatinine were 
observed. Several patients were identified to have mild, asymp-
tomatic hypokalemia during the course of the trial. These patients 
were treated with potassium replacement; however, the etiology of 
the hypokalemia was not felt to be a result of the anakinra therapy.
IL-1β plasma levels. We sought to determine the association 
between clinical responsiveness and biomarkers. Based on the 
rationale for this trial that elevated IL-1β may be associated with 
corticosteroid resistance, we focused our analysis on IL-1β. Plasma 
levels of IL-1β were measured at all interval visits. Notably, IL-1β 
plasma levels were generally associated with clinical response and, 
perhaps more importantly, with clinical relapse (Figure 3). During 
the 180 day post-treatment observation phase, 3 patients who expe-
rienced initial improvement in hearing while taking anakinra exhib-
ited relapse 30–90 days after its discontinuation (patients LIJ-01, 
Figure 2. Best hearing improvement observed while on anakinra therapy. 
PTA improvement (A) and WRS improvement (B) during the 84-day drug 
period were both significantly higher in anakinra responders (n = 7) versus 
nonresponders (n = 3) (P = 0.02 for both, Mann-Whitney test). The result 
was also compared with the historic improvement with corticosteroid 
therapy (Standard of care) previously reported by Niparko et al. (1).
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discontinued correlated with elevation of their IL-1β levels. Rein-
troduction of anakinra in patients LIJ-01 and LIJ-09 resulted in 
clinical hearing improvement again, albeit not to the degree seen 
with initial treatment. This observation supports our hypothesis 
that IL-1β is a critical mediator of immune-mediated SNHL, yet 
also underscores the potential need for long-term inhibition and/or 
and the subsequent 180-day observational period, this fluctuation 
in response to unknown stimuli is one of the clinical features of 
AIED. Notably, no clinical hearing improvement or fluctuation was 
observed in response to the initial corticosteroid therapy, as was 
requisite for entrance into the trial. Even more intriguing, clinical 
relapse within 30–90 days in several patients once anakinra was 
Figure 3. Hearing thresholds (PTA and WRS) relative to IL-1β plasma levels in a phase I/II trial of anakinra for corticosteroid-resistant AIED 
(NCT01267994). At visit 1, anakinra (daily subcutaneous injectable medication) was instituted (↑) for the next 84 days, after which therapy was discontinued 
(↓). Interval audiograms were obtained at visits 2 (day 28), 3 (day 56), and 4 (day 84). The 180-day post-treatment observational period is shown in visits 
5 (day 114), 6 (day 174), and 7 (day 264). The left axis shows PTA, plotted inversely, similar to an audiogram (lower numbers correspond to better hearing); 
solid lines denote active ears (blue, left; red, right), and dashed lines denote inactive ears. Numeric values show WRS for the active ear (blue, left; red, right), 
with a best possible score of 100. The right axis shows IL-1β plasma values (green). In some patients, after visit 4, anakinra treatment was reinstated for an 
additional 28 days (denoted by arrows) because of a decline in hearing. Institution of steroid therapy in patient LIJ-07 is denoted by a red arrow.
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longer-acting agents. To date, none of the interventional clinical 
trials on AIED patients have successfully correlated a plasma bio-
marker with pharmaceutical efficacy. Correlation of IL-1β levels 
with disease severity and efficacy of anakinra is therefore novel, 
and an important avenue of further exploration and validation.
IL-1 inhibition in AIED may represent yet another example of 
the spectrum of diseases in which IL-1 plays a pivotal role (18). Val-
idation of IL-1β inhibition through larger phase II and phase III tri-
als in AIED will determine efficacy in terms of hearing restoration 
as well as the potential of plasma IL-1β as a predictive biomarker of 
hearing fluctuation. Future clinical trials will also identify whether 
similar efficacy can be achieved in a more ethnically and racially 
diverse patient population. These data provide strong evidence 
that a placebo-controlled phase II trial of IL-1β inhibition in the 
corticosteroid-resistant AIED patients is warranted.
Methods
Patients. To be eligible for this clinical trial, the patient (age between 
13 and 75) must have bilateral SNHL, with active deterioration in 1 
ear, and must have failed to respond to high-dose corticosteroids 
(defined as taking 60 mg prednisone for 14 days followed by a taper, 
totaling 28 days of prednisone therapy). Specifically, patients must 
have SNHL of >30 dB at 1 or more frequencies in 1 or 2 ears with evi-
dence of active deterioration (elevated threshold) in at least 1 ear of 
15 dB at 1 frequency (excluding 250 or 8 kHz as a sole indicator) on 
their audiogram, or 10 dB at ≥2 frequencies developing in no less than 
3 and no more than 90 days; if the hearing loss evolved in less than 
3 days, the patient displayed features suggestive of an autoimmune 
disorder. Furthermore, hearing declines could not be accompanied 
by concurrent disabling vertigo, as this clinical presentation would be 
more consistent with Meniere’s disease.
The definition of steroid failure was exhibiting <5 dB PTA 
improvement (PTA defined as the average of 250, 500, 1,000, 2,000, 
and 4,000 Hz) and ≤12% WRS improvement. Since WRS was used as 
an endpoint, all enrolled patients were required to use English as their 
native language, as this test could not be administered in other lan-
guages by our study personnel. Concurrent intratympanic steroid ther-
apy may have been used, but could not substitute for oral therapy. All 
patients were of mixed European descent; age and gender are listed in 
Table 1. Patients may have concurrent autoimmune diseases (Table 1). 
Because AIED is a rare disease, recruitment of an untreated control 
group was not feasible. Moreover, a placebo arm was equally problem-
atic from ethical and practical standpoints, as anakinra requires daily 
subcutaneous injections. The likelihood of a placebo effect was highly 
improbable, as trial enrollment required 2 sequential audiograms, 
prior to and following steroids, which demonstrated no improvement 
with standard corticosteroid therapy.
Patients were excluded from study participation for radiologic 
abnormalities suggestive of alternate SNHL etiologies, evidence of 
chronic infection that would increase the risk of anakinra therapy, or 
laboratory abnormalities that would also increase the risk of anakinra 
therapy. MRI was used to exclude patients with retrocochlear pathol-
ogy (vestibular schwannoma) or inner ear malformations. Patients 
with a history of chronic infections, or treatment of a malignancy 
within 3 years prior to enrollment, were similarly excluded. Addi-
tionally, patients receiving recent methotrexate or TNF antagonist 
therapy were also prevented from participating. Patients that dem-
onstrated evidence of neutropenia or renal insufficiency or failure 
were also excluded. Finally, patients with latex allergy and allergy to 
E. coli–derived products were excluded because of the manner in 
which anakinra is formulated and packaged.
Experimental therapy. All eligible patients were treated with 84 
continuous days of 100 mg subcutaneous anakinra daily injections 
followed by a 180-day observational period to determine the stability 
of hearing following use of anakinra (Figure 1). Retreatment during 
the observational period was provided to patients that initially dem-
Table 2. Adverse event listings (all causalities)
Adverse eventA No. subjects 
reporting
Incidence  
rate
Severity Related to  
study treatment
Study day or range  
of event reported
Action taken
Injection site reaction 8 66.7% Mild Definite 10 ± 4 to 42 ± 20B Ice/site rotation
Injection site reaction 2 16.7% Moderate Definite 11 ± 1.4 to 23 ± 0.7B Regimen interrupted/study discontinued
Headache 4 33.33% Mild Possible 3–8, 1–3, 20–34, 81–102 None or additional OTC therapy
Vertigo 3 25% Mild Possible 9–11, 16–17, 20–34 None or additional therapy
Influenza-like illness 1 8.3% Mild Possible 43–47 None
Sinusitis 1 8.3% Mild Possible 65–84 Additional therapy (oral antibiotic)
Dermatitis 1 8.3% Mild Unlikely 148–151 Additional therapy (cortisone cream)
Nausea 2 16.7% Mild Possible 1–2, 16–17 None
Visual impairment (floaters) 1 8.3% Mild Possible 65 None
Arthralgia 1 8.3% Mild Unlikely 29–30 None
Wheezing 1 8.3% Moderate Possible 12 Regimen interrupted/study discontinued
Disturbance in attendance 1 8.3% Mild Possible 20–34 None
Tremor (hand) 1 8.3% Mild Unlikely 5–66 None
Anxiety 1 8.3% Mild Unlikely 63 None
Cellulitis 1 8.3% Mild Possible 40–46 Additional therapy (oral antibiotic)
Psoriasis (flare-up) 1 8.3% Mild Possible 31–42 None
Tinnitus 2 16.7% Mild Possible 222–236, 37–235 None
n = 12 subjects treated with anakinra. APreferred AE MedDRA term (version 2011.02). BRange ± SD.
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trial would enroll 19 additional subjects; if ≥6 of all 29 responded, 
then anakinra would be considered effective and a candidate for 
further larger trials. This design corresponded to testing the null 
hypothesis that the true objective response rate was ≤10% versus the 
alternative hypothesis that the true response rate was ≥30%, with 
α = 0.05 and power = 0.80.
Given that 2 sequential audiograms (before and after steroid ther-
apy) were required for trial eligibility, the likelihood of a placebo effect 
contributing to the observed hearing response was unlikely. Statistical 
significance between PTA and WRS of responders and nonresponders 
was calculated using 2-tailed Mann-Whitney test (Graph Pad Prism). A 
P value less than 0.05 was considered significant.
Study approval. We conducted these studies as a phase I/II 
open-label, single-arm, single-institution study. An IND to perform 
these studies, IRB approval from the North Shore–LIJ Health Sys-
tem, and clinical trial registry (NCT01267994) was obtained prior 
to the inception of the trial. Because A. Vambutas and the Feinstein 
Institute for Medical Research have filed a patent for the use of 
IL-1 antagonists in the treatment of AIED, SSNHL, and Meniere’s 
disease, an external DSMB was assembled to periodically review 
safety (approximately biyearly), and an internal monitoring system 
to assess safety and efficacy as well as to verify source data was also 
established and conducted by the Feinstein Institute for Medical 
Research Office of Research Compliance. Written, informed con-
sent was obtained from all enrolled patients from an investigator 
without a conflict of interest.
Assessment of adverse events. In order to ascertain the number, 
frequency, and duration of adverse events, patients were required to 
maintain daily symptom logs in addition to periodic review during 
interval visits. Adverse events are shown in Table 2. The daily ques-
tionnaire consisted of questions related to anticipated injection site 
reactions, change in hearing, or associated symptoms of tinnitus or 
vertigo. Furthermore, an open response field permitted the enrolled 
patient to report any new symptoms. Logs were reviewed daily as 
received, and unanticipated symptoms prompted follow-up by tele-
phone. In several cases, the patients were requested to return to the 
office for an unscheduled visit to better ascertain the severity of the 
adverse event. No serious adverse events were reported or recorded. 
In 2 cases, the drug was temporarily suspended because of an adverse 
event. In these cases, further drug was discontinued because of sig-
nificant, intolerable injection site reactions, 1 in combination with a 
presumptive allergic reaction manifested by wheezing.
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onstrated clinical improvement on anakinra, but exhibited relapse in 
the absence of drug. This consisted of 28 continuous days of 100 mg 
subcutaneous anakinra injections, followed by continued observation.
Measures of clinical improvement. Patients were reassessed a mini-
mum of 7 times during this clinical trial. Following the initial audio-
gram at the point of steroid failure, patients were reassessed every 
28 days while on anakinra (days 28, 56, and 84). They were reassessed 
on days 30, 90, and 180 of the observational period (days 114, 174, and 
264, respectively, relative to therapy initiation). Additionally, if they 
reported a hearing decline at any point during the entire trial, they 
were asked to return for audiometric testing. If retreated with anakinra 
for a confirmed decline in hearing, an audiogram at the 28th day of 
anakinra therapy was obtained.
Hearing was measured by several audiologists, all masked to prior 
audiograms. PTA was measured on a GSI-61 audiometer, calibrated 
every 3 months. WRS was performed by recorded speech, 50 word 
lists, rotating the track number at each visit, maintaining the same 
level of difficulty.
A positive clinical response was classified as an improvement in 
PTA hearing of ≥5 dB at the 5-frequency average described above, or 
a ≥12% improvement in WRS, at any point between the 28th and 84th 
day of trial participation. Although the criteria of a 15 dB improvement 
at 1 frequency or a 10 dB improvement at 2 frequencies has been previ-
ously used to measure responsiveness in other studies (14), this model 
does not account for evaluation at multiple time points, and thus could 
not be used in the present study.
The DSMB recommended closing the trial when >6 of a total 29 
evaluable patients achieved the efficacy target of PTA improvement 
between the 28th and 84th day of treatment with anakinra, as dictated 
by the Simon 2-stage design.
Safety laboratory measures. To screen for eligibility and to assess 
safety during the trial, a CBC with differential, and SMA-7 was 
obtained from all participants at each visit. A β-HCG was obtained in 
all female participants at each visit. Notably, 1 patient initially failed 
the screen for trial inclusion because of a positive β-HCG. This patient 
was enrolled >12 months later once she met eligibility criteria again. 
No patients failed screening or were prevented from using anakinra 
during the trial for concerns of neutropenia.
Experimental laboratory measures. At the time of initial enroll-
ment and at all visits, safety blood and blood biomarker identifi-
cation was obtained, with the hope that anakinra responders and 
nonresponders could be identified based on their peripheral blood 
expression of various cytokines, most importantly IL-1β and IL-1α. 
Plasma was collected and stored at –20°C until a complete set of 
samples was acquired for each enrolled subject. Frozen samples 
were thawed immediately prior to analysis, and none of the samples 
underwent repetitive freeze-thawing cycles prior to analysis. IL-1β 
and IL-1α levels in plasma were quantified using a sandwich ELISA 
(R&D Systems) as previously described (5). All samples were run in 
duplicate; mean variance was ≤0.02%.
Statistics and sample size calculation. Because steroid-resistant 
subjects were to be enrolled, and because we assumed that multiple 
etiologies may contribute to the failure to respond to steroids, we 
proposed that a ≤10% response rate would be unacceptable, and a 
≥30% response rate would be clinically meaningful and worthy of 
further study. A Simon 2-stage “optimal” design was used: 10 sub-
jects would be treated in the first stage; if 2 or more responded, the 
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